Company Information
CIN
Status
Date of Incorporation
19 September 1991
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2022
Last Annual Meeting
23 September 2022
Paid Up Capital
51,119,800
Authorised Capital
125,000,000
Directors
Manish Umed Doshi
Director
about 2 years ago
about 2 years ago
Vandana Manish Doshi
Director
about 2 years ago
about 2 years ago
Past Directors
Kundan Lal Khurana
Director
about 16 years ago
about 16 years ago
Mukundray Harshadray Bhatt
Director
about 16 years ago
about 16 years ago
Rupesh Suryakant Kamdar
Additional Director
about 17 years ago
about 17 years ago
Patents
The present invention provides an improved process for preparation of 1 -[[3-(6,7-dihydro-l-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4- ethoxyphenyI]sulphonyl]-4methypiperazine citrate (Sildenafil Citrate) of
Polymorphic form I)
The invention encompasses an improved process for the synthesis of Linagliptin, denoted by Formula-1 by deprotecting a tert-butyloxy carbony] (Boc)-protected compound of-Formula-Ill in presence of organic acids such as formic acid, sulfonic acids such as 4-methylbenzenesulfonic acid (PTSA), methanesulfonic acid (MSA...
The present invention provides a process for preparation of (S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide, compound of formula (1). Preferred embodiment of the process comprises;
(b) Further purify the resulting compound using suitable purification method.
(a) reacting (R)-N-5-(azid...
The present invention provides a process for preparation of (S)-N-({3-[3-fluoro-4-(morpholin-4-yl) phenyl]-2-oxo-l, 3-oxazolidin-5-yl} methyl) acetamide of formula I. The present invention further provides a process for the preparation of Form I of Linezolid of formula I.
The present application provides an improved process for the preparation of novel crystalline Celecoxib form Am of Formula (1) via condensation of 4,4,4-trifluoro-l-[4-(methyl)phenyl]-butane-l,3-dione of formula (2) with 4-sulphonamido phenylhydrazine hydrochloride of Formula (3) in water.
The compound of Formul...
Abstract
A Process for the preparation of Telmisartan of formula 1, and novel intermediates thereof, namely 4'-(bromomethyl)-N-hydroxybiphenyI-2-carboxamide compound of formula (3) and 4'-((l,4'-dimethyl-2'-propyl-2,6'-bi(lH-benzo[d]imidazol)-l'-yl)methyl)-N-hydroxybiphenyl-2-carboxamide compound of formula (5)
...
The present invention provides a process for manufacturing polymorph V of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride (Sertraline hydrochloride polymorph V) of the formula: comprising the steps of suspending salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-...
The present invention provides a process for preparation of 10,11-Dihydro-10-oxo-5H-dibenz[b, f]azepine-5-carboxamide, compound of formula (1). Preferred embodiment of the process comprises
reacting compound of formula (2) with alkaline earth or alkali metal isocynate in presence of weak acid to yield compound o...
The present invention provides a process for preparation of (S)-N-({3-[3-fluoro-4-(morpholin-4-yI) phenyl]-2-oxo-l, 3-oxazolidin-5-yl} methyl) acetamide of formula I. The present invention further provides a novel process for the preparation of Form I of Linezolid of formula I.
The present invention provides an improved process for the preparation of Venlafaxine and the intermediates thereof. The present invention provides a process for preparing compound of formula IV an intermediate for preparing Venlafaxine by hydrogenating a compound of formula-III: (III) in the presence of toluene, wa...
The object of invention is providing the efficient process for preparation of Apixaban and its intermediate formula-Ill, name as ethyl l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-l-yl)phenyl]-4,5,6,7-tetrahydro-lH-pyrazol-[3,4-c]pyridine-3-carbvoxylate by using ethyl 6-(4-iodophenyl)-l-(4-methoxyphenyl)-7-oxo-4)5...
The invention encompasses a Crystalline Form-A of Dihydralazine mesylate and process for its preparation.
1,4-dihydrazinyl-1,4-dihydrophthalazine methanesulfonate
Formula I
The invention encompasses a one pot process for the preparation of Clotrimazole which comprises-
a) Reacting o-chlorophenyi diphenyl chloromethane of Formula 2 with imidazole of Formula 3 in a solvent such as acetone or toluene and triethyl amine at reflux temperature;
b) Optionally washing the organi...
Abstract
The present invention relates to a process for the preparation of bis[2-(dimethylamino)ethyl] succinate an intermediate of succinyl choline chloride. It further relates to process for the preparation of succinyl choline chloride or pharmaceutically acceptable dehydrates thereof from the above intermediate....
The present invention relates to a novel process for the preparation of an eslicarbazepine intermediate (S)-acetyl mandelate of formula VII and further conversion of the above intermediate to eslicarbazepine of formula I.
.An improved process for preparation of 10 - 0x0 -10,1 l-dihydro-5H-dibenz[b,fj azepine -5 - carboxamide (oxcarbazepine) from 10-methoxy-5H-dibenz[b,f]azepine (10-methoxy iminostilbene) comprising the following steps,a) reacting 10-methoxyiminostilbene with sodium cyanate and monochrloro acetic acid us...
The present invention relates to an improved process for the preparation of key intermediate of Deferasirox "2-(2-hydroxyphenyl)-4H-benzo(e)[1,3]oxazin-4-one" by reacting Salicylic acid, thionyl chloride and Salicylamide in presence of a catalyst and solvent and further preparation of Deferasirox from the above inte...
The present invention describes an improved process for the preparation of Carbamazepine. The process involves reacting 5H-dibenzo[b,f]azepine-5-carbonyl chloride with an liquid ammonia in the presence of Methyl isobutyl ketone to obtain Carbamazepine.
The present invention relates to an improved process for the preparation of Apixaban and N-1 polymorph thereof.
The present invention relates to a process for the preparation of a key intermediate "(R)-2-[(2-(4-aminophenyl)ethyl)amino]-1-phenylethanol" or its hydrochloride of Mirabegron and process for the synthesis of Mirabegron therefrom.
Registered Trademarks
[Class : 1] Descalants For Industrial Use
Renewal of trademark is due. Renewal request in prescribed form is to be filed by the applicant.
Charges
14 May 2019
Dbs Bank India Limited
30 Crore
27 April 2018
State Bank Of India
173 Crore
26 April 2018
State Bank Of India
139 Crore
18 January 2018
Dbs Bank Ltd
2 Crore
19 December 2017
Icici Bank Limited
9 Crore
24 August 2016
State Bank Of India
184 Crore
01 August 2015
Icici Bank Limited
5 Crore
15 December 2014
Dbs Bank Ltd
75 Lak
16 September 2014
Dbs Bank Ltd
11 Crore
13 February 2014
Dbs Bank Ltd
18 Crore
06 September 2013
Dbs Bank Ltd
9 Crore
26 April 2012
Icici Bank Limited
12 Crore
15 September 2006
Icici Bank Limited
14 Crore
08 February 2005
Icici Bank Limited
27 Crore
04 January 1999
State Bank Of India
33 Crore
07 June 2021
Hdfc Bank Limited
20 Crore
25 June 2020
State Bank Of India
5 Crore
18 May 2020
Indusind Bank Ltd.
22 Crore
08 February 2005
Icici Bank Limited
0
15 September 2006
Icici Bank Limited
0
26 April 2012
Icici Bank Limited
0
24 August 2016
State Bank Of India
0
26 April 2018
State Bank Of India
0
25 June 2020
State Bank Of India
0
01 August 2015
Icici Bank Limited
0
27 April 2018
State Bank Of India
0
06 September 2013
Dbs Bank Ltd
0
15 December 2014
Dbs Bank Ltd
0
13 February 2014
Dbs Bank Ltd
0
04 January 1999
State Bank Of India
0
16 September 2014
Dbs Bank Ltd
0
08 February 2005
Icici Bank Limited
0
15 September 2006
Icici Bank Limited
0
26 April 2012
Icici Bank Limited
0
24 August 2016
State Bank Of India
0
26 April 2018
State Bank Of India
0
25 June 2020
State Bank Of India
0
01 August 2015
Icici Bank Limited
0
27 April 2018
State Bank Of India
0
06 September 2013
Dbs Bank Ltd
0
15 December 2014
Dbs Bank Ltd
0
13 February 2014
Dbs Bank Ltd
0
04 January 1999
State Bank Of India
0
16 September 2014
Dbs Bank Ltd
0
Documents
Form AOC-4(XBRL)-03042021_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20210224
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-31122020
Instrument(s) of creation or modification of charge;-30122020
Form CHG-1-30122020
Particulars of all joint charge holders;-30122020
Form DPT-3-29122020_signed
Form MSME FORM I-29122020_signed
Particulars of all joint charge holders;-23122020
Optional Attachment-(1)-23122020
Instrument(s) of creation or modification of charge;-23122020
Form CHG-1-23122020
Form MSME FORM I-08122020_signed
Form MGT-14-09112020_signed
Altered articles of association-09112020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-09112020
Optional Attachment-(2)-08072020
Form CHG-1-08072020_signed
Optional Attachment-(1)-08072020
Optional Attachment-(4)-08072020
Instrument(s) of creation or modification of charge;-08072020
Optional Attachment-(3)-08072020
CERTIFICATE OF REGISTRATION OF CHARGE-20200708
Letter of the charge holder stating that the amount has been satisfied-02072020
Form CHG-4-02072020_signed
CERTIFICATE OF SATISFACTION OF CHARGE-20200702
Instrument(s) of creation or modification of charge;-29062020
Particulars of all joint charge holders;-29062020
Form CHG-1-29062020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200629
